Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a pioneering genetic medicines company dedicated to the development of transformative therapies for rare monogenic central nervous system (CNS) diseases. Leveraging cutting-edge gene therapy techniques, Passage Bio is advancing a robust pipeline aimed at addressing unmet medical needs in both pediatric and adult CNS disorders.
The company's key initiatives include the development of PBGM01 for infantile GM1 gangliosidosis, PBFT02 for frontotemporal dementia (FTD) caused by progranulin deficiency, and PBKR03 for infantile Krabbe disease. These therapies utilize proprietary adeno-associated virus (AAV) capsids to deliver functional genes directly to the brain and peripheral tissues, promising significant therapeutic benefits.
Passage Bio collaborates with leading institutions to bolster its research and development efforts. This includes a strategic research partnership with the University of Pennsylvania's Gene Therapy Program and a collaboration agreement with Catalent Maryland, Inc. Such alliances enhance Passage Bio's capacity to innovate and expedite the clinical development of its promising therapies.
Financially, Passage Bio is in a strong position, with a cash runway extending into the fourth quarter of 2025, allowing the company to diligently progress its clinical programs. Recent achievements include positive interim data from the Imagine-1 study, a Phase 1/2 clinical trial of PBGM01, demonstrating a favorable safety profile and initial evidence of efficacy in early and late infantile GM1 gangliosidosis.
Additionally, the company is making strides with PBFT02. Initial data from the upliFT-D clinical trial indicate promising safety and biomarker outcomes, showing elevated cerebrospinal fluid (CSF) progranulin levels. Such results underscore the potential of PBFT02 to address the underlying pathology of FTD and other neurodegenerative conditions.
Passage Bio is also committed to fostering the next generation of scientists through initiatives like the Tachi Yamada Scholarship program, which supports students in life sciences disciplines.
Passage Bio (Nasdaq: PASG) has granted an inducement award of options to purchase 82,000 shares of its common stock to a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.05 per share, matching the closing price on the grant date, April 17, 2023. The options will vest over four years, with 25% vesting on the one-year anniversary and the remaining in 36 equal monthly installments, subject to continued employment. The company focuses on developing therapies for central nervous system disorders, including GM1 gangliosidosis and frontotemporal dementia, and has a collaboration with the University of Pennsylvania’s Gene Therapy Program. Further details about its gene therapy pipeline can be found on their official website.
Passage Bio, a clinical stage genetic medicines company focused on central nervous system (CNS) disorders, announced that its CEO William Chou, M.D., and CTO Alex Fotopoulos will participate in a virtual fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023, at 3:30 p.m. ET.
The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days after. Passage Bio is dedicated to developing therapies for CNS diseases, currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia, and has a robust preclinical pipeline targeting amyotrophic lateral sclerosis and Huntington’s disease. The company collaborates with the University of Pennsylvania’s Gene Therapy Program, enhancing its research capabilities and access to innovative gene therapy candidates.
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company, announced that CEO William Chou, M.D., will take part in a fireside chat at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on April 3, 2023, at 3:55 p.m. ET in New York. A live webcast of the chat will be available on the company's Investors & Media section. Passage Bio focuses on developing transformative therapies for central nervous system (CNS) disorders, including GM1 gangliosidosis and frontotemporal dementia, with strong collaborations enhancing their research capabilities.
Passage Bio (NASDAQ: PASG) reported promising interim data for PBGM01 in GM1 gangliosidosis during the 19th Annual WORLDSymposium™, showing a biological effect in the first six patients. The company plans to expand the Imagine-1 study to include higher doses and expects initial safety data from Cohort 4 by mid-2023. Financial results highlighted a cash position of $189.6 million, sufficient to fund operations through the first half of 2025. The net loss for Q4 2022 stood at $27.1 million, while R&D expenses decreased to $17.7 million. The company anticipates key results from its upliFT-D trial in FTD by late 2023.
Passage Bio, a clinical-stage genetic medicines company (Nasdaq: PASG), announces the opening of its Tachi Yamada Scholarship program for rising juniors majoring in life sciences at Pennsylvania colleges. The $10,000 scholarship, awarded annually, aims to support students committed to careers in life sciences. Applications are due by April 1, 2023, for the initial award in fall 2023. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former chairman of the board, who championed mentorship in the field. The selected scholar will also receive mentorship opportunities over two years for professional development.
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company, announced CEO William Chou will participate in a corporate panel at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET in Boston, MA. This event will focus on therapies for central nervous system disorders. A live webcast will be accessible on Passage Bio's website, with a replay available for 30 days post-event. The company is advancing treatments for CNS diseases, including GM1 gangliosidosis and frontotemporal dementia, leveraging a collaboration with the University of Pennsylvania's Gene Therapy Program.
Passage Bio (NASDAQ: PASG) announced a conference call on March 6, 2023, at 8:30 a.m. ET to discuss its Q4 and full-year 2022 financial results and recent business developments. The company focuses on developing gene therapies for central nervous system disorders, including GM1 gangliosidosis and frontotemporal dementia. Through a collaboration with the University of Pennsylvania’s Gene Therapy Program, Passage Bio enhances its access to gene therapy candidates, leveraging its clinical and regulatory expertise. Investors can access the webcast on the company's website post-event.
Passage Bio, Inc. (Nasdaq: PASG) announced new data from its Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis, presented at the 19th Annual WORLD Symposium. The updated interim results indicate that PBGM01 administration led to stabilization of MRI severity scores in all treated patients over a follow-up of 6 to 12 months, suggesting positive biological effects. Additionally, decreases in urine levels of β-Gal substrate Dp5 were observed, indicating increased β-Gal activity. The therapy shows a favorable safety profile with no serious adverse events reported, bolstering confidence in PBGM01 as a potential treatment option for this rare disease.
FAQ
What is the current stock price of Passage Bio (PASG)?
What is the market cap of Passage Bio (PASG)?
What does Passage Bio, Inc. specialize in?
What are some of the key products in Passage Bio’s pipeline?
Who are Passage Bio’s key collaborators?
What is the focus of the Imagine-1 clinical study?
What recent advancements has Passage Bio made?
What is PBGM01?
What is the purpose of the Tachi Yamada Scholarship program?
When does Passage Bio expect to release additional data from their clinical trials?
What are the financial highlights of Passage Bio?
What is PBFT02 and what conditions does it target?
